Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

90 Presentations At Radiation Oncology Meeting Demonstrate Breadth And Depth Of Clinical Evidence For Accuray Inc


Thursday, 8 Nov 2012 08:30am EST 

Accuray Inc announced that studies presented at the 54th Annual American Society for Radiation Oncology (ASTRO) Meeting in Boston, October 28-31, 2012 continue to demonstrate the unique strengths of the CyberKnife and TomoTherapy Systems. Podium and poster presentations on a variety of indications including prostate, lung, liver, breast and head and neck, showcased Accuray's position as a in radiation oncology. TomoTherapy researchers demonstrated the benefits of and the ability to create high-quality treatment plans that maximally spare nearby healthy tissues, for simple-to-complex targets throughout the body. Also highlighted was the capability to deliver the treatment plans accurately and with guidance from fully integrated daily 3D megavoltage computed tomography (MVCT), reinforcing the flexibility of the TomoTherapy System to treat a wide array of radiotherapy needs. Data on the CyberKnife System that was presented at ASTRO 2012 continued to support the use of the CyberKnife System to deliver large radiation doses conformally and accurately to lesions of the lung, liver, prostate, and elsewhere throughout the body. The CyberKnife System's ability to track moving targets and automatically correct for motion in real time continues to provide clinicians the confidence to deliver radiosurgery and SBRT throughout the body, even to sites surrounded by healthy tissue and critical structures. 

Company Quote

8.26
0.16 +1.98%
22 Aug 2014